European Commission approval of new indication for Roche's Pegasys offers hepatitis C patients a second chance for a cure Pegasys is the first and only pegylated interferon to be approved for ...

resilience. pharma& anticipates eligible European patients should start to experience improved Pegasys availability in the coming weeks. “We are thrilled to announce the EMA’s approval for Pegasys API ...

Hoffmann-La Roche Inc. received FDA clearance to sell Pegasys, a pegylated interferon for the treatment of hepatitis C, making it the second drug on the market for this disease developed using ...

Roche's Pegasys receives EU approval for the treatment of chronic hepatitis C in children five years of age and older Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that the European Medicines ...

MHRA approves Loba Biotech to manufacture Pegasys API, enabling pharma& to strengthen UK supply and ensure continued access for eligible patients. Following the MHRA decision, pharma& expects that ...

An experimental new combination of drugs for hepatitis C cures more patients with fewer side effects than the standard treatment for the potentially deadly, liver-destroying infection, researchers say ...

Swiss drugmaker, Roche, moved a step closer to bringing the first long-acting interferon alpha product to the European Union’s chronic hepatitis B market after its Pegasys (peginterferon alfa-2a) drug ...

July 25, 2005 — The European Commission has approved moxifloxacin HCl intravenous infusion for the treatment of complicated skin and skin structure infections; the Scottish Medicines Consortium has ...

Feb. 7, 2005 -- The European Commission has approved an expanded indication for peginterferon alfa-2a injection, allowing its use in the European Union for the treatment of hepatitis C virus in ...

Pegasys and Peg-Intron between them share the bulk of an estimated $2 billion global market for HCV treatments, predicted to grow to around $4 billion in 2013. Five years ago, Peg-Intron dominated the ...